Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Pembrolizumab + XL888 for Advanced Gastrointestinal Cancer
Recruiting1 awardPhase 1
Atlanta, Georgia
This trial is testing the side effects and best dose of XL888 when given with pembrolizumab to treat patients with advanced gastrointestinal cancer. XL888 may stop tumor growth by blocking enzymes needed for cell growth. Pembrolizumab may block tumor growth by targeting certain cells. Giving XL888 with pembrolizumab may work better to treat patients with gastrointestinal cancer.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.